Clinical trials: Colorectal Cancer Liver Metastases (CRLM)
Colorectal Cancer Metastatic
Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLM
To observe the PFS of yttrium [90Y] microsphere injection combined with FOLFIRI and bevacizumab in second-line treatment of CRLM.
- Trial name
- NCT06447727
- Testing
- SIRT with Yttrium-90 Microspheres, FOLFIRI and Bevacizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhongda Hospital
Colorectal Cancer Liver Metastases (CRLM)
AI-Based Prediction of Liver Metastasis in Colorectal Cancer (A Retrospective Study)
This multicenter, retrospective study aims to develop and validate a multimodal deep learning model for predicting the risk of metachronous liver metastasis in patients with stage I-III colorectal cancer following curative…
- Trial name
- NCT07399236
- Testing
- Multimodal Deep Learning Model Analysis
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Tongji Hospital
Colorectal Cancer (Diagnosis), Colorectal Liver Metastasis (CRLM)
Feasibility of Circulating Tumour DNA (ctDNA) Analysis Using Automated Capillary Blood Sampling
The goal of this observational study is to investigate whether circulating tumor-derived DNA (ctDNA) can be reliably detected and analyzed in blood obtained through automated capillary sampling in adult patients (≥21 years) with…
- Conditions
- Colorectal Cancer (Diagnosis), Colorectal Liver Metastasis (CRLM), Circulating Tumor DNA (ctDNA)
- Trial name
- ctDNA TAP (NCT07310537)
- Testing
- Blood Collection - TAP® Device, Blood Collection - Venous
- Where
- Netherlands
- Volunteers
- 35 people
- Sponsor
- Erasmus Medical Center
Colorectal Cancer, Liver Metastases
Prognostic Factors and Oncological Outcomes in Laparoscopic Liver Resection for CRLM
Laparoscopic liver resection (LLR) has gained acceptance as an effective treatment for colorectal liver metastases (CRLM) in selected patients, providing similar oncologic outcomes compared to open liver resection (OLR).
- Conditions
- Colorectal Cancer, Liver Metastases, Surgery
- Trial name
- NCT05036265
- Volunteers
- 200 people
- Sponsor
- General Hospital Groeninge
Colorectal Cancer Liver Metastases (CRLM), Colorectal Cancer
Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases
This is a prospective, single-center, single-arm exploratory clinical study designed to evaluate the efficacy and safety of hepatic arterial infusion of liposomal irinotecan combined with systemic oxaliplatin and capecitabine as…
- Conditions
- Colorectal Cancer Liver Metastases (CRLM), Colorectal Cancer, Liver Metastasis
- Trial name
- NCT07570914
- Testing
- Liposomal Irinotecan, Oxaliplatin, Capecitabine
- Volunteers
- 28 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Colorectal Neoplasms
Hepatic Arterial Infusion Pump Chemotherapy Combined With Systemic Chemotherapy (PUMP-IT)
The PUMP-IT study is designed to prove the feasibility of HAIP chemotherapy with concomitant standard systemic chemotherapy (FOLFOX and FOLFIRI) in the Netherlands.
- Trial name
- PUMP-IT (NCT04552093)
- Testing
- Floxuridine, Tricumed IP2000V infusion pump
- Where
- Netherlands
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- The Netherlands Cancer Institute
Liver Metastasis Colon Cancer
Treatment With Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic FOLFIRI Chemotherapy and Bevacuzimab in Patients With Liver-only Colorectal Liver Metastases (CRLM): Conversion to Complete Resection in Patients With Initially Inoperable Liver-only CRLM.
A few studies have documented that some patients can be down-staged from an initially inoperable state to a potentially resectable state.
- Trial name
- NCT04003792
- Testing
- oxaliplatin, FOLFIRI Protocol, Bevacizumab
- Where
- Israel
- Volunteers
- 49 people
- Sponsor
- Rabin Medical Center
Colorectal Cancer, Liver Metastases
Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM
For patients with initially resectable colorectal cancer liver metastases who have high-risk factors, neoadjuvant therapy is currently considered a consensus approach.
- Trial name
- NCT05948072
- Testing
- mFOLFOX6 + Cetuximab, mFOLFOX 6
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Fudan University
Colorectal Adenocarcinoma Metastatic to the Liver
TACE(Transcatheter Arterial Chemoembolization ) Associated With Systemic Chemotherapy Versus Systemic Chemotherapy Alone in Patients With Unresectable CRLM(Colorectal Liver Metastases)
To date no randomized controlled trials have been completed that demonstrated whether TACE(Transarterial chemoembolization) is an effective adjunct to systemic chemotherapy (target therapy) with respect to advantages in…
- Trial name
- NCT03783559
- Testing
- TACE, chemotherapy±target therapy
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Fudan University
Colorectal Cancer, Liver Metastases
Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM
HARVEST is an investigator-initiated prospective randomized controlled study comparing adjuvant intravenous systemic chemotherapy with or without HAI- floxuridine (FUDR) in CRC patients post-liver metastasectomy.
- Conditions
- Colorectal Cancer, Liver Metastases, HAI
- Trial name
- NCT03500874
- Testing
- FUDR, Oxaliplatin, Leucovorin
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Sun Yat-sen University
Colon Adenocarcinoma, Liver Metastasis Colon Cancer
LDLT in Non Resectable Colo-rectal Cancer Liver Metastasis
This study is an interventional open label prospective study that aims to assess both overall and disease-free survival of patients treated with LDLT, partial or whole graft LT from deceased donors for unresectable CRLM.
- Trial name
- LIVERMORE (NCT05186116)
- Testing
- Living donor liver transplant, Split liver transplant, RAPID, DDLT
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Modena
Colorectal Liver Metastasis (CRLM), Histopathological Growth Patterns (HGPs)
Deep Learning-Based Analysis of Colorectal Cancer Pathology Images: An Innovative Approach for Predicting Colorectal Cancer Subtypes
Colorectal cancer (CRC) is a leading cause of mortality in China, with metastasis significantly contributing to poor outcomes. Histopathological growth patterns (HGPs) in colorectal liver metastasis (CRLM) provide vital…
- Conditions
- Colorectal Liver Metastasis (CRLM), Histopathological Growth Patterns (HGPs), Artificial Intelligence (AI) in Diagnosis, Vision Transformer (ViT)
- Trial name
- NCT06936098
- Testing
- CRLM surgery
- Where
- China
- Volunteers
- 431 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Colorectal Neoplasms Malignant
Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM
The goal of this clinical trial is to investigate the effectiveness of localized interventions in improving the 5-year survival rate for colorectal cancer patients with ≥10 liver metastases.
- Trial name
- NCT06208371
- Testing
- Surgical resection and/or ablation therapy and/or SBRT, Palliative Chemotherapy
- Where
- China
- Volunteers
- 117 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer, Liver Metastases
Dose Finding, Efficacy and Immunological Response of IP-001 Following MWA or IRE for CRLM
The primary objectives of this phase I/II, prospective clinical trial, are to assess the optimal dose, efficacy, safety and immunological effect of ablation and intra-tumoral injection of a novel immuno-adjuvant (IP-001) for…
- Conditions
- Colorectal Cancer, Liver Metastases, Liver Metastasis Colon Cancer
- Trial name
- INJECTABL-II (NCT06630624)
- Testing
- IP-001
- Where
- Netherlands
- Volunteers
- 120 people
- Sponsor
- M.R. Meijerink
Liver Neoplasms, Hepatobiliary Diseases
Outcomes After Liver and Biliary Resection at a High-Volume Center
The goal of this observational study is to evaluate clinical and oncologic outcomes in adult patients undergoing liver and/or biliary resection for benign and malignant diseases.
- Conditions
- Liver Neoplasms, Hepatobiliary Diseases, Cholangiocarcinoma, Hepatocellular Carcinoma
- Trial name
- BILIVER (NCT07556835)
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- Azienda USL Toscana Centro
Hepatocellular Carcinoma, Hepatocellular Cancer
Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC
This is a single arm phase II study of adjuvant intra-dermal NA DC vaccine combined with intravenous nivolumab in patients with resectable HCC (group A) or CRLM (group B) planned for curative surgery (with/without local ablation).
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Colorectal Cancer, Colorectal Carcinoma
- Trial name
- NCT04912765
- Testing
- Neoantigen Dendritic Cell Vaccine, Nivolumab
- Where
- Singapore
- Volunteers
- 60 people
- Sponsor
- National Cancer Centre, Singapore
Colorectal Cancer Liver Metastases (CRLM)
AK104 Plus Radiotherapy Combined With Standard Therapy Versus Standard Therapy as First-Line Treatment for pMMR/MSS CRLM (APSOC)
This is a prospective, randomized controlled, single-center phase II clinical study. It aims to compare the efficacy of AK104 plus radiotherapy combined with standard therapy versus standard therapy as first-line treatment for…
- Trial name
- APSOC (NCT07544784)
- Testing
- AK104 with radiotherapy, Standard of therapy
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Fudan University
Long-term Oncologic Outcome of MILS in Patients With CRLM and Prognostic Indicators
Minimally Invasive Liver Surgery for Metastases From Colorectal Cancer: Oncologic Outcome and Prognostic Factors
Only few reports exist on long-term survival after minimally invasive liver surgery (MILS for colorectal liver metastases. No data are available assessing prognostic factors in the era of current modern treatment strategies.
- Trial name
- NCT01356706
- Where
- Belgium
- Volunteers
- 274 people
- Sponsor
- University Hospital, Gasthuisberg
Colorectal Cancer Liver Metastasis
Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM
To date no prospective trials have been completed that demonstrated whether RFA is an effective adjunct to systemic chemotherapy (target therapy) with respect to advantages in overall survival compared with chemotherapy (target…
- Trial name
- NCT03127072
- Testing
- Radiofrequency Ablation (RFA), chemotherapy ± target therapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Fudan University